C4 Therapeutics (CCCC) Equity Average (2019 - 2025)
Historic Equity Average for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $164.2 million.
- C4 Therapeutics' Equity Average fell 3292.57% to $164.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.2 million, marking a year-over-year decrease of 3292.57%. This contributed to the annual value of $231.0 million for FY2024, which is 1368.23% down from last year.
- As of Q3 2025, C4 Therapeutics' Equity Average stood at $164.2 million, which was down 3292.57% from $184.6 million recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' Equity Average peaked at $407.6 million during Q3 2021, and registered a low of $164.2 million during Q3 2025.
- Moreover, its 5-year median value for Equity Average was $252.7 million (2024), whereas its average is $278.6 million.
- Per our database at Business Quant, C4 Therapeutics' Equity Average soared by 53138.06% in 2021 and then tumbled by 3292.57% in 2025.
- Over the past 5 years, C4 Therapeutics' Equity Average (Quarter) stood at $394.2 million in 2021, then decreased by 22.95% to $303.7 million in 2022, then decreased by 23.92% to $231.1 million in 2023, then decreased by 0.76% to $229.3 million in 2024, then decreased by 28.38% to $164.2 million in 2025.
- Its Equity Average was $164.2 million in Q3 2025, compared to $184.6 million in Q2 2025 and $205.6 million in Q1 2025.